BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?

BCR::ABL1 tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal condition into a chronic ailment. With optimal management, the survival of CML patients diagnosed in the chronic phase is approaching that of age-matched controls. However, only one-third of patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2024-09, Vol.38 (9), p.1885-1893
Hauptverfasser:	Cruz-Rodriguez, Nataly, Tang, Hua, Bateman, Benjamin, Tang, Weiping, Deininger, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	13 631/67/1059/153 631/80/86 64/60 82 82/1 Animals Biodegradation Cancer Research Chimeras Chronic myeloid leukemia Critical Care Medicine Degradation Drug Resistance, Neoplasm Functionals Fusion Proteins, bcr-abl - antagonists & inhibitors Fusion Proteins, bcr-abl - metabolism Hematology Humans Intensive Internal Medicine Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemogenesis Medicine Medicine & Public Health Myeloid leukemia Oncology Patients Phase matching Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proteins Proteolysis Proteolysis Targeting Chimera Proto-Oncogene Proteins c-abl - metabolism Remission Review Article Stem cells Tyrosine Tyrosine kinase inhibitors Ubiquitin-protein ligase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!